



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/699,003

Art Unit: 3772

Filed: October 26, 2000

Examiner: P. Bianco

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including four (4) pages of Form PTO-1449 and copies of the thirty-two (32) documents cited therein. Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of U.S. Patents and Published Applications are not enclosed. Copies will be provided upon request, however.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(d) after a Notice of Allowance. Most of the references cited herein were cited in connection with Interference No. 105,413 involving related U.S Application Serial No. 09/709,045.

U.S.S.N.: 09/699,003  
Filed: October 26, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

### U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,439,332	03-27-1984	Frank	507/225
4,863,611	09-05-1989	Bernstein	210/661
5,610,279	03-11-1997	Brockhaus	530/387.3
5,712,291	06-27-1998	D'Amato	514/323
5,808,029	09-15-1998	Brockhaus	536/23.5
6,133,431	10-17-2000	Yusada	530/413

### U.S. Patent Applications

<u>Number</u>	<u>Publication Date</u>	<u>Inventor</u>	<u>Class/Subclass</u>
2005-0265996 A1	12-01-2005	Lentz	424/133
09/709,045	11-10-2000	Lentz	424/0085
09/699,003	10-26-2000	Lentz	604/008

### Publications

AGISHI, Anion-blood contact (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors (letter). *JAMA*; 271:195-6(1994).

BANYAI et al., "Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis," *Metabolism* 47(9):1058-1064 (1998).

CYTOLOGIC, "Unleash Immunotherapy," CytoLogic non CDA info.doc , pp.1-10 (April 27, 2006).

DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nucl. Acids Res.* 19: 2471-2476 (1991).

GUYTON and HALL, Textbook of Medical Physiology 9<sup>th</sup> ed. Pp. 299

HARLOW et al., *Antibodies, A Laboratory Manual*, Chapter 13, "Immunoaffinity Purification," pp. 511-552, 1988

Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R. W., et al.,p. 263 (J.B.Lippincott, Philadelphia, PA 1987),

HONG et al., "Intercellular adhesion molecule-1 expression induced by interleukin (IL)-1 beta or an IL-1 beta fragment is blocked by an IL-1 receptor antagonist and a soluble IL-1 receptor," *Journal of Neuroimmunology*, 44(2):163-170 (1993).

IBM Technical Disclosure Bulletin, Vol 19, No 3. August 1976 pp. 765-768

JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," *Arch Immunol Ther Exp (Warsz)*. 45(5-6):449-53 (1997).

JANEWAY, et al. Immunobiology: The Immune System in Health and Disease, 4<sup>th</sup> Ed. Pp.102

KAMINSKA, et al. „Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor," *Tumour Biol*. 26(4):186-94(2005).

KAMINSKA, et al "Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor," *Oncology* 70(2):115-25(2006).

KOJIMA, et al. "Effect of nafamostat mesilate on bradykinin generation during lowdensity lipoprotein apheresis using a dextran sulfate cellulose column," *ASAIO Trans* 37: 644-8(1991).

MARUYAMA, et al. "Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering," *Cell*. 48(2):343-350(1987).

MITTEREGGER, et al., "In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment", *Ther Apher.*, 3(3):257-63 (1999).

NATIONAL CANCER INSTITUTE, "Biological Therapies for Cancer: Questions and Answers," National Cancer Institute FactSheet (08-16-2004).

OLD, Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): Tumor Necrosis Factor/Cachecin and Related Cytokines, Basell, Karger, p7 (1988).

PALASZYNSKI," Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor," *Biochemical and Biophysical Research Communications*, 147(1):204-211(1987).

PENNICA et al., "Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregationm," *Biochemistry* 31(4):1134-1141(1992).

PENNICA et al., "Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor," *Biochemistry* 32(12): 3131-3138(1993).

Product description: catalog number AB-225-PB catalog of R&D Systems. (1994).

Product description: catalog number AB-226-PB catalog of R&D Systems (1994).

Product description: catalog numbers FAB225F catalog of R&D Systems (1998).

Product description: catalog numbers MAB225 catalog of R&D Systems (1998).,

Product description: catalog numbers AF-425-PB catalog of R&D Systems (1998).

Product description: of antibody AHR3912. Biosource catalog

SHIBATA, et al., "Changes of cell-mediated immunity with an advance of cancer-relation to the th1/th2 balance and inhibitors of th1 cytokines", *Biotherapy*, 12(5):715-17 (1998).

VERMA et al., "Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems," *Journal of Immunological Methods*, 216(1-2):165-181(1998).

WARZOGA, et al. "Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients," *J Clin Oncol.* 15(2):499-508(1997).

WINTER, et al. "Synthetic human antibodies and a strategy for protein engineering," *FEBS Letters*, 430:92-94(1998).

YAMAZAKI et al. Biocompatibility of plasma separator of an improved cellulose acetate hollow fiber. In: Sieberth HG (ed). Plasma Exchange. New York: fk Schattauer, 45-51(1980).

U.S.S.N.: 09/699,003  
Filed: October 26, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'Patrea L. Pabst', written over a horizontal line.

Patrea L. Pabst  
Reg. No. 31,284

Dated: October 17, 2007  
PABST PATENT GROUP LLP  
400 Colony Square, Suite 1200  
1201 Peachtree Street  
Atlanta, Georgia 30361  
(404) 879-2151 (Telephone)  
(404) 879-2160 (Fax)